In the US, heart disease remains the most common cause of death. Because a large volume of functional muscle is replaced by fibrotic scar following a large myocardial infarction, there has been tremendous interest in strategies to regenerate the diseased myocardium. Cell therapy is appealing to provide cells that will ideally regenerate the damaged heart; however, the results of clinical trials to date have not shown clear benefit in most cases from cell therapy. The lack of robust clinical benefit could be due to multiple factors, but particularly we suggest that the optimal cell preparations have not been tested. The cell populations with the most robust capacity to form new cardiac muscle are cardiac progenitors present during heart development. Therefore, our central hypothesis is that distinct populations of cardiac progenitor cells can be isolated from the native heart or pluripotent stem cells as well as by direct reprogramming of somatic cells that will exhibit superior ability to repair the injured myocardium compared to differentiated cell types. However, we have incomplete understanding of the distinct cardiac progenitor populations responsible for the developing heart, and our ability to isolate these cardiac progenitors is limited. We propose to address these limitations in three aims: 1) identify and isolate first heart field, left ventriclar progenitor cells from developing mouse heart and mESCs; 2) test transplantation of CPCs and direct in vivo reprogramming to iCPCs in cardiac repair post-MI; and 3) generate proliferative, multipotent human induced CPCs. This research will advance our understanding of cardiac progenitors, provide new tools for the isolation and study of CPCs, and test powerful new approaches for post-MI cardiac repair.

Public Health Relevance

Many forms of heart disease are caused by the death of functioning cardiac muscle cells with scar forming. The goal of this research is to provide better definition of the progenitor cells present in development that form heart muscle and to use that understanding to advance new approaches for repair of the diseased heart.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL129798-01
Application #
8988235
Study Section
Special Emphasis Panel (ZRG1-CVRS-B (02))
Program Officer
Buxton, Denis B
Project Start
2015-07-10
Project End
2019-04-30
Budget Start
2015-07-10
Budget End
2016-04-30
Support Year
1
Fiscal Year
2015
Total Cost
$378,260
Indirect Cost
$128,260
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Garg, Priyanka; Garg, Vivek; Shrestha, Rajani et al. (2018) Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as Models for Cardiac Channelopathies: A Primer for Non-Electrophysiologists. Circ Res 123:224-243
Bylund, Jeffery B; Trinh, Linh T; Awgulewitsch, Cassandra P et al. (2017) Coordinated Proliferation and Differentiation of Human-Induced Pluripotent Stem Cell-Derived Cardiac Progenitor Cells Depend on Bone Morphogenetic Protein Signaling Regulation by GREMLIN 2. Stem Cells Dev 26:678-693
Yanamandala, Mounica; Zhu, Wuqiang; Garry, Daniel J et al. (2017) Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering. J Am Coll Cardiol 70:766-775
Lalit, Pratik A; Rodriguez, Adriana M; Downs, Karen M et al. (2017) Generation of multipotent induced cardiac progenitor cells from mouse fibroblasts and potency testing in ex vivo mouse embryos. Nat Protoc 12:1029-1054
Nelson, Daryl O; Lalit, Pratik A; Biermann, Mitch et al. (2016) Irx4 Marks a Multipotent, Ventricular-Specific Progenitor Cell. Stem Cells 34:2875-2888
Lalit, Pratik A; Salick, Max R; Nelson, Daryl O et al. (2016) Lineage Reprogramming of Fibroblasts into Proliferative Induced Cardiac Progenitor Cells by Defined Factors. Cell Stem Cell 18:354-67
Vaidyanathan, Ravi; Markandeya, Yogananda S; Kamp, Timothy J et al. (2016) IK1-enhanced human-induced pluripotent stem cell-derived cardiomyocytes: an improved cardiomyocyte model to investigate inherited arrhythmia syndromes. Am J Physiol Heart Circ Physiol 310:H1611-21